Provided herein are methods, compositions and kits for use in the site-specific labeling of glycoproteins comprising a combination of enzyme-mediated incorporation of modified sugars comprising a chemical handle and cycloaddition chemistry with a labeling molecule comprising a reactive group, a metal ion chelator, and/or a fluorophore.

The present invention relates to an IgG-binding peptide comprising a ligand capable of binding to a radioactive metal nuclide, an IgG-binding peptide labeled with a radioactive metal nuclide, a conjugate of the IgG-binding peptide and IgG, and a radionuclide imaging agent or a diagnostic agent for cancer comprising the IgG-binding peptide or the conjugate, etc.

The present invention relates to an IgG-binding peptide comprising a ligand capable of binding to a radioactive metal nuclide, an IgG-binding peptide labeled with a radioactive metal nuclide, a conjugate of the IgG-binding peptide and IgG, and a radionuclide imaging agent or a diagnostic agent for cancer comprising the IgG-binding peptide or the conjugate, etc.

A composition for imaging a tumorous disease region includes a fluorescence- or radioactive isotope-labeled ERBB2 aptamer, wherein the ERBB2 aptamer labeled with a radioactive isotope or a fluorescent dye is used to image the tumorous disease region in vivo. The composition may include a labeled hybridized aptamer comprising an aptamer represented as formula 1 hybridized with a labeled-ODN represented as formula 2.

A composition for imaging a tumorous disease region includes a fluorescence- or radioactive isotope-labeled ERBB2 aptamer, wherein the ERBB2 aptamer labeled with a radioactive isotope or a fluorescent dye is used to image the tumorous disease region in vivo. The composition may include a labeled hybridized aptamer comprising an aptamer represented as formula 1 hybridized with a labeled-ODN represented as formula 2.

The present disclosure is directed to methods (e.g., in vitro methods) for use of nicotinamide phosphoribosyltransferase (NAMPT) as a biomarker in radiation-induced lung injury (RILI). Provided herein is an in vitro method for the diagnosis, prognosis, and/or monitoring of RILI in a human subject by providing a tissue or plasma sample from the subject and detecting the level of NAMPT therein, wherein a higher level of NAMPT in the tissue or plasma sample from the subject compared to a healthy control or a reference value is indicative for the presence of RILI in the subject. Further provided herein is a method of detecting NAMPT in a human subject by obtaining a biological sample from the subject, detecting the presence of NAMPT in the sample by contacting the sample with a capture agent that specifically binds NAMPT, and detecting binding between NAMPT and the capture agent.

The present disclosure is directed to methods (e.g., in vitro methods) for use of nicotinamide phosphoribosyltransferase (NAMPT) as a biomarker in radiation-induced lung injury (RILI). Provided herein is an in vitro method for the diagnosis, prognosis, and/or monitoring of RILI in a human subject by providing a tissue or plasma sample from the subject and detecting the level of NAMPT therein, wherein a higher level of NAMPT in the tissue or plasma sample from the subject compared to a healthy control or a reference value is indicative for the presence of RILI in the subject. Further provided herein is a method of detecting NAMPT in a human subject by obtaining a biological sample from the subject, detecting the presence of NAMPT in the sample by contacting the sample with a capture agent that specifically binds NAMPT, and detecting binding between NAMPT and the capture agent.

Disclosed are P2X7 receptor ligands having the formula (I):

##STR00001##

in which R=(CH.sub.2).sub.n(OCH.sub.2CH.sub.2).sub.mO.sub.l(CH.sub.2).sub.pX, l=0-1, m=0-6, n=2-3, p=0-2, and X=Br, Cl, F or .sup.18F. In illustrative embodiments, R=(CH.sub.2).sub.n, and n=2-3. The receptor ligands are used in methods related to conditions related to the P2X7 receptor. The non-radioligands are useful for modulating inflammation conditions associated with the P2X7 receptor. The radioligands, containing .sup.18F, are useful for as radiotracers in imaging processes, and thus for the detection and evaluation of inflammation and therapies. Also provided are processes for preparation of these P2X7 receptor ligands.

Disclosed are P2X7 receptor ligands having the formula (I):

##STR00001##

in which R=(CH.sub.2).sub.n(OCH.sub.2CH.sub.2).sub.mO.sub.l(CH.sub.2).sub.pX, l=0-1, m=0-6, n=2-3, p=0-2, and X=Br, Cl, F or .sup.18F. In illustrative embodiments, R=(CH.sub.2).sub.n, and n=2-3. The receptor ligands are used in methods related to conditions related to the P2X7 receptor. The non-radioligands are useful for modulating inflammation conditions associated with the P2X7 receptor. The radioligands, containing .sup.18F, are useful for as radiotracers in imaging processes, and thus for the detection and evaluation of inflammation and therapies. Also provided are processes for preparation of these P2X7 receptor ligands.

The present disclosure relates to a method for labeling a radioisotope, a radiolabeling compound, a kit including the same, and a method for labeling a radioisotope, including: providing a diaminophenyl compound represented by Chemical Formula I below and including a biomolecule, a fluorescent dye or a nanoparticle compound bound thereto; and reacting the diaminophenyl compound and a radioisotope-labeled aldehyde compound represented by Chemical Formula II below at room temperature; and a related technology:

##STR00001## in Chemical Formula I, A is CH.sub.2 or O; a is 0 or an integer of 1 to 10; X is CH.sub.2 or CONH; Y is CH.sub.2 or

##STR00002##

and Z is the biomolecule, the fluorescent dye or the nanoparticle compound,

##STR00003## in Chemical Formula II, b is 0 or an integer of 1 to 10; and L is CH.sub.2 or CONH; and Q is or

##STR00004## M, M and M in Q are radioisotopes.